Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study.
Yan Hiu Athena LeeJeremy Man Ho HuiSteven Chi Ho LeungChristopher Tze-Wei TsangKyle HuiPias TangJeffrey Shi Kai ChanEdward Christopher DeeKenrick NgSean McBridePaul L NguyenGary TseChi-Fai NgPublished in: Prostate cancer and prostatic diseases (2023)
Enzalutamide was associated with lower cardiovascular risks than abiraterone in PCa patients.
Keyphrases
- prostate cancer
- cardiovascular events
- end stage renal disease
- radical prostatectomy
- coronary artery disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- cardiovascular disease
- peritoneal dialysis
- prognostic factors
- emergency department
- type diabetes
- patient reported outcomes
- risk assessment
- adverse drug
- drug induced